2HA Stock Overview
A clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Spero Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$1.75 |
| 52 Week Low | US$0.95 |
| Beta | 0.63 |
| 11 Month Change | -2.29% |
| 3 Month Change | -8.73% |
| 1 Year Change | 2.97% |
| 33 Year Change | -91.61% |
| 5 Year Change | -89.64% |
| Change since IPO | -89.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2HA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.2% | -0.7% | 0.2% |
| 1Y | 3.0% | -17.2% | 8.5% |
Return vs Industry: 2HA exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 2HA underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 2HA volatility | |
|---|---|
| 2HA Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 2HA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2HA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 46 | Sath Shukla | sperotherapeutics.com |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd.
Spero Therapeutics, Inc. Fundamentals Summary
| 2HA fundamental statistics | |
|---|---|
| Market cap | €60.73m |
| Earnings (TTM) | €3.37m |
| Revenue (TTM) | €102.23m |
18.0x
P/E Ratio0.6x
P/S RatioIs 2HA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2HA income statement (TTM) | |
|---|---|
| Revenue | US$106.46m |
| Cost of Revenue | US$51.56m |
| Gross Profit | US$54.90m |
| Other Expenses | US$51.39m |
| Earnings | US$3.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.064 |
| Gross Margin | 51.57% |
| Net Profit Margin | 3.30% |
| Debt/Equity Ratio | 0% |
How did 2HA perform over the long term?
See historical performance and comparison